Highlights
NCI asked the Institute of Medicine (IOM) of the National Academies to review the NCI Clinical Trials Cooperative Group Program in order to gather independent and expert perspectives on the state of cancer clinical trials and to obtain advice about improvements in the NCI Cooperative Group Program. To learn more about NCI's response to the IOM Report, visit NCI's Progress on IOM Goals and Recommendation.
Available to funded Cooperative Groups (CGs) and Community Clinical Oncology Program (CCOP) Research Bases to support essential biomarker, imaging, and quality of life studies associated with clinical trial concepts for large (at least 100 patients), randomized phase 2 therapeutic trials and phase 3 therapeutic, cancer prevention, and primary symptom management clinical trials. Additional eligibility this year is for phase 3 studies with an embedded Cost-Effectiveness Analysis (CEA) study. This is an "open competition" announcement with no specific receipt date.
The 22 Clinical Trials Working Group (CTWG) initiatives can be broadly categorized as addressing coordination, scientific prioritization, standardization, operational efficiency, and enterprise-wide concerns.
A central element of NCI's efforts to transform the clinical trials enterprise is the organization of Scientific Steering Committees composed of outside cancer experts and NCI senior investigators.